Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Advisory Committee Votes In Favor Of SAPHRIS(R) (asenapine) For Acute Bipolar I Disorder And Acute Schizophrenia
Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted unanimously in favor of SAPHRIS(R) (asenapine) sublingual tablets as effective and safe for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and in favor of use in acute treatment of schizophrenia in adults. If approved by FDA, SAPHRIS would be the first psychotropic drug to be approved initially for both of these indications.
generic viagra online
Also In Global Health News: Noncommunicable Disease Network; Tropical Disease Treatments; Maternal Health In Peru; South Asia MDG
WHO Launches International Network To Take On Noncommunicable Disease
News of the day
MS Society Commends Federal Government's Research Investment In Neurological Diseases
The Multiple Sclerosis Society of Canada praised the government"s announcement of $15 million to study the impact of a wide variety of neurological conditions, including multiple sclerosis.
Sexual Health

Development Of DNA Drugs Gives Hope To Lupus Patients

A generation of DNA-like compounds, class R inhibitory oligonucleotides (INH-ODNs), have been shown to effectively inhibit cells responsible for the chronic autoimmune condition lupus. Researchers writing in BioMed Central"s open access journal Arthritis Research & Therapy have demonstrated the anti-inflammatory effects of the INH-ODNs in both in vitro and mouse experiments. Petar Lenert, from the University of Iowa, worked with a team of researchers to develop and test the compounds. He said, "The increased potency of class R INH-ODNs for certain cells involved in lupus flare-ups will help patients by providing specific inhibition, yet allowing them to generate a protective immune response when needed". Lenert and his colleagues found that their INH-ODN drugs, composed of double-stranded DNA-like analogues carrying autoimmune-inhibitory sequences, were able to selectively reduce the activity of autoreactive B cells and dendritic cells. When given to mice with lupus, the compounds delayed death and reduced kidney damage. Systemic lupus erythematosus, more commonly known simply as lupus, is thought to affect around a million people in the USA, but prevalence varies by country and ethnicity. It is much more common in women than men and there is currently no known cure. During periodic "flares", the immune system of people with the condition mounts an attack on cells and tissues throughout the body, resulting in a range of symptoms including the characteristic "butterfly rash" across the cheeks. With further testing, Lenert and his colleagues hope that class R INH-ODNs may become another weapon in the fight against the disease. DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas lpr/lpr mice in vivo Petar Lenert, Kei Yasuda, Liliana Busconi, Patrice Nelson, Courtney Fleenor, Radhika S Ratnabalasuriar, Peter L Nagy, Robert F Ashman, Ian R Rifkin and Ann Marshak-Rothstein Arthritis Research & Therapy http://arthritis-research.com/ Graeme Baldwin BioMed Central


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009